Click to copy
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Click to copy
PRESS RELEASE: Paid content from Globe Newswire
Press release content from Globe Newswire. The AP news staff was not involved in its creation.

BeiGene to Hold Conference Call and Webcast on September 8, 2019 at 7:00 p.m. ET to Provide Corporate Update

September 8, 2019

CAMBRIDGE, Mass. and BEIJING, China, Sept. 08, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, announced that the company will hold a conference call and webcast on Sunday, September 8, 2019, at 7:00 p.m. ET | Monday, September 9, 2019, at 7:00 a.m. Hong Kong time, prior to the open of trading on the Hong Kong Stock Exchange. On the call, Company management will provide information related to a recent short seller report commenting on the Company’s operations.

Conference Call and Webcast InformationInvestors and analysts are invited to join the conference call using the following dial-in information:U.S. Toll-Free: (844) 461-9930Hong Kong: 5819-4851China: 400-682-8609Conference ID: 7797578

A live webcast of the conference call can be accessed from the investors section of BeiGene’s website at http://ir.beigene.com/ or http://hkexir.beigene.com. An archived replay will be available two hours after the event for 90 days.

About BeiGene

BeiGene is a global, commercial-stage, research-based biotechnology company focused on molecularly-targeted and immuno-oncology cancer therapeutics. With a team of over 2,700 employees in China, the United States, Australia and Europe, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is also working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients. BeiGene markets ABRAXANE® (nanoparticle albumin–bound paclitaxel), REVLIMID® (lenalidomide), and VIDAZA® (azacitidine) in China under a license from Celgene Corporation.1

Investor Contact Media Contact Craig West Liza Heapes +1 857-302-5189 + 1 857-302-5663 ir@beigene.com media@beigene.com

1 ABRAXANE®, REVLIMID® and VIDAZA® are registered trademarks of Celgene Corporation.

All contents © copyright 2019 The Associated Press. All rights reserved.